Serum high density lipoprotein – LCn3 – HDL, mmol/L · adults with or without existing CVD
1 finding from 1 review
Serum low‐density lipoprotein (LDL, mmol/L) · adults with or without existing CVD
2 findings from 1 review
Measures of adiposity – ALA – Weight, kg · adults with or without existing CVD
1 finding from 1 review
Serum total cholesterol – ALA – TC, mmol/L · adults with or without existing CVD
1 finding from 1 review
Serum triglyceride, ALA ‐ fasting TG, mmol/L · adults with or without existing CVD
1 finding from 1 review
Cardiovascular events · adults with or without existing CVD
High showed no clear difference in cardiovascular events compared with low long‐chain omega‐3 fats (high certainty).
1 finding from 1 review
Serum high density lipoprotein – ALA – HDL, mmol/L · adults with or without existing CVD
1 finding from 1 review
Coronary heart disease mortality – CHD deaths · adults with or without existing CVD
High showed no clear difference in coronary heart disease mortality – CHD deaths compared with low long‐chain omega‐3 fats (low certainty).
1 finding from 1 review
CHD events · adults with or without existing CVD
High may leads to lower coronary heart disease events – CHD events compared with low long‐chain omega‐3 fats (low certainty).
1 finding from 1 review
Stroke · adults with or without existing CVD
High showed no clear difference in stroke compared with low long‐chain omega‐3 fats (moderate certainty).
1 finding from 1 review
Arrhythmias · adults with or without existing CVD
High showed no clear difference in arrhythmias compared with low long‐chain omega‐3 fats (low certainty).
1 finding from 1 review
Harms: bleeding · adults with or without existing CVD
It is very uncertain whether high changes harms: bleeding compared with low long‐chain omega‐3 fats (very low certainty).
1 finding from 1 review
Harms: pulmonary embolus or DVT · adults with or without existing CVD
It is very uncertain whether high changes harms: pulmonary embolus or DVT compared with low long‐chain omega‐3 fats (very low certainty).
1 finding from 1 review
Change in dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in score indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in dry eye symptoms, measured using the OSDI score (ranging… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Tear film stability · people with dry eyea
Combined oral omega‐3 and omega‐6 PUFAs showed no clear difference in change in tear film stability, measured using tear break‐up time… compared with placebo (moderate certainty).
1 finding from 1 review
Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea
1 finding from 1 review
Adverse event: gastrointestinal disorders at 1‐month (with actual · people with dry eyea
1 finding from 1 review
Dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in scores indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral omega‐3 PUFAs plus conventional therapy showed no clear difference in dry eye symptoms, measured using the OSDI score (ranging from 0 to… compared with conventional therapy alone (low certainty).
1 finding from 1 review
Ocular surface staining · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Aqueous tear production · people with dry eyea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found